Gustavo A. Rosario Benitez

Array ( [id] => 13479139 [patent_doc_number] => 20180291112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation [patent_app_type] => utility [patent_app_number] => 15/950633 [patent_app_country] => US [patent_app_date] => 2018-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 73062 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15950633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16061367 [patent_doc_number] => 10689618 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-23 [patent_title] => T cell receptor-deficient T cell compositions [patent_app_type] => utility [patent_app_number] => 15/948303 [patent_app_country] => US [patent_app_date] => 2018-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 13985 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 275 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15948303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16721358 [patent_doc_number] => 20210088505 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => Unipotent Neutrophil Progenitor Cells, Methods of Preparation, and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/603522 [patent_app_country] => US [patent_app_date] => 2018-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20344 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16603522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13342897 [patent_doc_number] => 20180222988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => THERAPEUTIC AGENT FOR CHRONIC ARTHRITIDES DISEASES OF CHILDHOOD-RELATED DISEASES [patent_app_type] => utility [patent_app_number] => 15/946866 [patent_app_country] => US [patent_app_date] => 2018-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11475 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15946866 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16605986 [patent_doc_number] => 10906978 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-02 [patent_title] => Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 [patent_app_type] => utility [patent_app_number] => 15/943685 [patent_app_country] => US [patent_app_date] => 2018-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 17 [patent_no_of_words] => 69590 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15943685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17821538 [patent_doc_number] => 11426462 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-30 [patent_title] => Monovalent anti-CD3 adjuvants [patent_app_type] => utility [patent_app_number] => 15/943420 [patent_app_country] => US [patent_app_date] => 2018-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 33 [patent_no_of_words] => 7186 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 155 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15943420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17541176 [patent_doc_number] => 11306289 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-19 [patent_title] => Methods of using IL-21 for adoptive immunotherapy and identification of tumor antigens [patent_app_type] => utility [patent_app_number] => 15/926874 [patent_app_country] => US [patent_app_date] => 2018-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 11622 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15926874 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18559974 [patent_doc_number] => 11725210 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-15 [patent_title] => Immunomodulatory fusion proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 16/494729 [patent_app_country] => US [patent_app_date] => 2018-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 106 [patent_figures_cnt] => 104 [patent_no_of_words] => 42877 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16494729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13986521 [patent_doc_number] => 20190062418 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => USE OF TNF ALPHA INHIBITOR [patent_app_type] => utility [patent_app_number] => 15/920987 [patent_app_country] => US [patent_app_date] => 2018-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22600 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15920987 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17435935 [patent_doc_number] => 11261247 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-01 [patent_title] => Modulators [patent_app_type] => utility [patent_app_number] => 15/921176 [patent_app_country] => US [patent_app_date] => 2018-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 59 [patent_figures_cnt] => 112 [patent_no_of_words] => 70308 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15921176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13957929 [patent_doc_number] => 20190055308 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFalpha-RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 15/915615 [patent_app_country] => US [patent_app_date] => 2018-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45792 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15915615 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13479137 [patent_doc_number] => 20180291111 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation [patent_app_type] => utility [patent_app_number] => 15/909423 [patent_app_country] => US [patent_app_date] => 2018-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 93024 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15909423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13383689 [patent_doc_number] => 20180243386 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => IDENTIFICATION OF CD8+ T CELLS THAT ARE CD161HI AND/OR IL18R(ALPHA)HI AND HAVE RAPID DRUG EFFLUX CAPACITY [patent_app_type] => utility [patent_app_number] => 15/903214 [patent_app_country] => US [patent_app_date] => 2018-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12171 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15903214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17904336 [patent_doc_number] => 11458169 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-04 [patent_title] => TIM3-binding chimeric antigen receptors [patent_app_type] => utility [patent_app_number] => 16/485296 [patent_app_country] => US [patent_app_date] => 2018-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 59 [patent_no_of_words] => 31921 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16485296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18315262 [patent_doc_number] => 11629333 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-18 [patent_title] => Gamma delta T cells and a method of augmenting the tumoricidal activity of the same [patent_app_type] => utility [patent_app_number] => 16/484427 [patent_app_country] => US [patent_app_date] => 2018-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 17 [patent_no_of_words] => 10317 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16484427 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13357779 [patent_doc_number] => 20180230429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 15/888897 [patent_app_country] => US [patent_app_date] => 2018-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44846 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15888897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15293585 [patent_doc_number] => 20190389928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => CD28 COMPOSITIONS AND METHODS FOR CHIMERIC ANTIGEN RECEPTOR THERAPY [patent_app_type] => utility [patent_app_number] => 16/481181 [patent_app_country] => US [patent_app_date] => 2018-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 111673 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16481181 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18101207 [patent_doc_number] => 11541076 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Chimeric antigen receptors targeting TIM-1 [patent_app_type] => utility [patent_app_number] => 16/477609 [patent_app_country] => US [patent_app_date] => 2018-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 38 [patent_no_of_words] => 38879 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16477609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13371963 [patent_doc_number] => 20180237522 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => ANTI-ALPHABETATCR ANTIBODY [patent_app_type] => utility [patent_app_number] => 15/867364 [patent_app_country] => US [patent_app_date] => 2018-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13010 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15867364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15038677 [patent_doc_number] => 20190330343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => METHODS AND COMPOSITIONS RELATING TO EX VIVO CULTURE AND MODULATION OF T CELLS [patent_app_type] => utility [patent_app_number] => 16/476592 [patent_app_country] => US [patent_app_date] => 2018-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21178 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16476592 [rel_patent_id] =>[rel_patent_doc_number] =>)